US Stock MarketDetailed Quotes
SYRE Spyre Therapeutics
- 27.000
- -0.500-1.82%
Close Nov 21 16:00 ET
- 27.000
- 0.0000.00%
Post 16:20 ET
1.59BMarket Cap-9722P/E (TTM)
29.090High26.760Low820.95KVolume27.590Open27.500Pre Close22.32MTurnover2.04%Turnover RatioLossP/E (Static)58.71MShares47.97052wk High9.24P/B1.09BFloat Cap10.42052wk Low--Dividend TTM40.21MShs Float318.750Historical High--Div YieldTTM8.47%Amplitude2.650Historical Low27.183Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Spyre Therapeutics Stock Forum
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
Spyre Therapeutics (NASDAQ: SYRE) has priced its public offering of 7,275,000 common stock shares at $27.50 per share, expecting to raise $200.0 million in gross proceeds. The clinical-stage biotech company, focused on IBD treatments, has granted underwriters a 30-day option to purchase up to additional 1,091,250 shares. The offering, managed by Jefferies, Goldman Sachs, Evercor...
Capital Markets: $UP Fintech (TIGR.US)$ $Cipher Mining (CIFR.US)$ $CleanSpark (CLSK.US)$
Biotechnology: $Genfit (GNFT.US)$ $Spyre Therapeutics (SYRE.US)$ $Krystal Biotech (KRYS.US)$
Software: $Verb Technology (VERB.US)$ $SurgePays (SURG.US)$ $Uber Technologies (UBER.US)$
Asset Management: $Westwood Holdings (WHG.US)$ $BrightSphere Investment (BSIG.US)$ $Blackrock (BLK.US)$
Specialty Industrial Machinery: $JE Cleantech Holdings Limited (JCSE.US)$ $Taylor Devices (TAYD.US)$ $CSW Industrials (CSWI.US)$
...
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average (.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index (.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index (.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks (DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...
No comment yet